Nov. 21 at 7:14 AM
$CUPR I’m on it.
Dear Peter,
Thank you for your email and for your continued interest in Cuprina Holdings.
Our focus remains on executing our business strategy and advancing our scientific and commercial milestones, which we believe support long-term shareholder value. These include, but are not limited to:
Advancing our chronic wound care pipeline and related collaborations, such as the recently announced joint venture with Aiodine Laboratory to develop and market a new iodine-based wound care therapy.
Progressing our broader portfolio of wound, fertility and medical-waste solutions, including the UNIDO/GEF-linked medical waste recycling technology and other initiatives that we believe can expand Cuprina’s long-term revenue base.
Continuing to invest in scientific leadership and IP, including the appointment of Dr. Ronald A. Sherman as Medical & Scientific Director and associated licensing arrangements.
Kind regards,
Investor Relations
Cuprina Holdings
